| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Stem Neoplasms | 5 | 2022 | 42 | 1.890 |
Why?
|
| Glioma | 11 | 2024 | 492 | 1.440 |
Why?
|
| Chemoradiotherapy | 5 | 2024 | 103 | 1.410 |
Why?
|
| Brain Neoplasms | 19 | 2024 | 1216 | 1.370 |
Why?
|
| Medulloblastoma | 12 | 2024 | 325 | 1.130 |
Why?
|
| Cerebellar Neoplasms | 10 | 2024 | 275 | 1.090 |
Why?
|
| Astrocytoma | 4 | 2022 | 100 | 0.830 |
Why?
|
| Germinoma | 4 | 2023 | 30 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1254 | 0.570 |
Why?
|
| Benzimidazoles | 2 | 2020 | 133 | 0.570 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2017 | 19 | 0.570 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2023 | 197 | 0.560 |
Why?
|
| Oximes | 1 | 2017 | 55 | 0.560 |
Why?
|
| Proton Therapy | 4 | 2024 | 123 | 0.540 |
Why?
|
| Glioblastoma | 5 | 2023 | 330 | 0.540 |
Why?
|
| Imidazoles | 1 | 2017 | 203 | 0.520 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 188 | 0.500 |
Why?
|
| Cochlea | 3 | 2024 | 86 | 0.450 |
Why?
|
| Hearing Loss | 3 | 2024 | 135 | 0.420 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1497 | 0.410 |
Why?
|
| Mutation, Missense | 1 | 2017 | 875 | 0.410 |
Why?
|
| Child | 38 | 2024 | 24407 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2023 | 889 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 293 | 0.320 |
Why?
|
| Radiotherapy Dosage | 9 | 2021 | 183 | 0.310 |
Why?
|
| Photons | 2 | 2019 | 48 | 0.300 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2014 | 70 | 0.290 |
Why?
|
| Child, Preschool | 22 | 2024 | 14022 | 0.280 |
Why?
|
| Cisplatin | 3 | 2024 | 249 | 0.270 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2024 | 72 | 0.260 |
Why?
|
| AC133 Antigen | 2 | 2024 | 35 | 0.260 |
Why?
|
| Adolescent | 22 | 2024 | 19355 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1694 | 0.240 |
Why?
|
| Radiation Injuries | 3 | 2019 | 142 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 620 | 0.230 |
Why?
|
| Humans | 48 | 2024 | 125195 | 0.230 |
Why?
|
| CD57 Antigens | 1 | 2024 | 5 | 0.230 |
Why?
|
| Formaldehyde | 1 | 2004 | 36 | 0.220 |
Why?
|
| Tissue Fixation | 1 | 2004 | 38 | 0.220 |
Why?
|
| Ethanol | 1 | 2004 | 163 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 73 | 0.200 |
Why?
|
| Rhabdoid Tumor | 2 | 2021 | 46 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 85 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5176 | 0.200 |
Why?
|
| Hydroxamic Acids | 1 | 2022 | 56 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 69 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 62 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2022 | 75 | 0.190 |
Why?
|
| Male | 27 | 2024 | 61524 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 62 | 0.190 |
Why?
|
| Brain | 5 | 2021 | 2999 | 0.190 |
Why?
|
| Pituitary Neoplasms | 2 | 2014 | 80 | 0.180 |
Why?
|
| Ependymoma | 1 | 2022 | 125 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 43 | 0.180 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 21 | 0.180 |
Why?
|
| RNA, Messenger | 4 | 2014 | 2821 | 0.180 |
Why?
|
| Craniospinal Irradiation | 1 | 2021 | 58 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 108 | 0.170 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 211 | 0.170 |
Why?
|
| Female | 29 | 2024 | 66803 | 0.170 |
Why?
|
| Young Adult | 7 | 2024 | 9056 | 0.170 |
Why?
|
| Bevacizumab | 1 | 2020 | 64 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 281 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 2064 | 0.170 |
Why?
|
| Teratoma | 2 | 2018 | 120 | 0.160 |
Why?
|
| Mice | 11 | 2024 | 17637 | 0.160 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 41 | 0.160 |
Why?
|
| Ganglioglioma | 2 | 2011 | 22 | 0.160 |
Why?
|
| Valproic Acid | 1 | 2020 | 165 | 0.160 |
Why?
|
| Mice, SCID | 5 | 2023 | 569 | 0.160 |
Why?
|
| SMARCB1 Protein | 1 | 2018 | 37 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 581 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 470 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 2048 | 0.150 |
Why?
|
| Prognosis | 4 | 2024 | 4641 | 0.150 |
Why?
|
| Capecitabine | 1 | 2017 | 16 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2022 | 1007 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 36 | 0.140 |
Why?
|
| Infant | 9 | 2021 | 12507 | 0.140 |
Why?
|
| Craniopharyngioma | 2 | 2014 | 33 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1893 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 4395 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 376 | 0.130 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2014 | 50 | 0.130 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 3348 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 399 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 57 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 723 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 1290 | 0.120 |
Why?
|
| Protein Kinase C beta | 1 | 2014 | 21 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1112 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 837 | 0.120 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 27 | 0.120 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2024 | 16344 | 0.110 |
Why?
|
| Animals | 12 | 2024 | 34238 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 36 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 189 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2024 | 39 | 0.110 |
Why?
|
| Mutation | 3 | 2024 | 5842 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2024 | 53 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 256 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 84 | 0.110 |
Why?
|
| DNA Mismatch Repair | 2 | 2024 | 50 | 0.100 |
Why?
|
| Cranial Irradiation | 2 | 2010 | 67 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 432 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 783 | 0.100 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 13 | 0.100 |
Why?
|
| Topotecan | 1 | 2012 | 48 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 898 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 699 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2014 | 370 | 0.100 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2012 | 12 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2023 | 286 | 0.100 |
Why?
|
| Brain Edema | 1 | 2012 | 68 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 72 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 811 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 210 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 107 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 29639 | 0.090 |
Why?
|
| Chromosome Duplication | 1 | 2011 | 147 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 625 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 272 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 156 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1711 | 0.080 |
Why?
|
| Pituitary Diseases | 1 | 2009 | 12 | 0.080 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 32 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1725 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 55 | 0.070 |
Why?
|
| Disease Progression | 3 | 2021 | 2064 | 0.070 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2007 | 20 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1420 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 122 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1241 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 576 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 1016 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 120 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 124 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 185 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1142 | 0.060 |
Why?
|
| Vision Disorders | 2 | 2021 | 211 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 245 | 0.060 |
Why?
|
| Microdissection | 1 | 2004 | 12 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 33 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2017 | 684 | 0.060 |
Why?
|
| Phenylacetates | 1 | 2004 | 23 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 63 | 0.050 |
Why?
|
| Lasers | 1 | 2004 | 114 | 0.050 |
Why?
|
| Phenylbutyrates | 1 | 2004 | 58 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 794 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 6159 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1696 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 3572 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 668 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1695 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 14 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1438 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2023 | 302 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 61 | 0.050 |
Why?
|
| Dissection | 1 | 2021 | 54 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 57 | 0.050 |
Why?
|
| Morpholines | 1 | 2021 | 57 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 154 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 341 | 0.050 |
Why?
|
| Benzamides | 1 | 2021 | 109 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 94 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2017 | 12396 | 0.050 |
Why?
|
| Basal Ganglia | 1 | 2021 | 56 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 92 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 118 | 0.040 |
Why?
|
| Thalamus | 1 | 2021 | 83 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1056 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 333 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1328 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1896 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 164 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 1272 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 192 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8228 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 69 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 110 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 2019 | 115 | 0.040 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2018 | 15 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 2823 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 27 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2636 | 0.040 |
Why?
|
| Hearing | 1 | 2018 | 52 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 678 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 48 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 480 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2018 | 135 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 847 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1276 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 135 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 191 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 255 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 202 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3146 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2021 | 816 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 949 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 270 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 173 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 880 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3430 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2174 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10312 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1101 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.030 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 37 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 302 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 526 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 606 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2312 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6336 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 676 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 258 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 151 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 515 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 483 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 686 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 708 | 0.030 |
Why?
|
| Carboplatin | 1 | 2013 | 76 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 43 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 13 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2006 | 618 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 59 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 144 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 663 | 0.020 |
Why?
|
| Vincristine | 1 | 2013 | 193 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 192 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 506 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 163 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1506 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 356 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 489 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1499 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 255 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 762 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3465 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 3102 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2012 | 279 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1631 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 339 | 0.020 |
Why?
|
| Amifostine | 1 | 2010 | 14 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2010 | 24 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1755 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 822 | 0.020 |
Why?
|
| Sella Turcica | 1 | 2009 | 3 | 0.020 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 341 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 363 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 375 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2009 | 82 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2013 | 552 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Cognition | 1 | 2013 | 731 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 172 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 111 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1020 | 0.020 |
Why?
|
| Anaplasia | 1 | 2007 | 6 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 24 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 31 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 48 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 23 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2006 | 230 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2006 | 281 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3588 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2004 | 16 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 126 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 657 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 67 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 26938 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 184 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 782 | 0.010 |
Why?
|
| United States | 1 | 2017 | 10921 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1614 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1102 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 797 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 2564 | 0.010 |
Why?
|
| Histones | 1 | 2004 | 525 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19881 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1806 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1898 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 1932 | 0.010 |
Why?
|